VEGFR2 expression and TGF-β signaling in initial and recurrent high-grade human glioma

Oncology

Volumn 81, Issue 2, 2011, Pages 126-134

  Kuczynski, Elizabeth A ^a   Patten, Steven G ^a   Coomber, Brenda L ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

Angiogenesis; Endothelial cell; KDR; Malignant glioma; Smad; Vascular endothelial growth factor receptor

Indexed keywords

SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; ENDOTHELIUM CELL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR RECURRENCE;

ADULT; AGED; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; RECURRENCE; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 80053502219     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000332849     Document Type: Article

References (40)

1. Massagué J: TGFbeta in Cancer. Cell 2008;134:215-230.
2. Ikushima H, Miyazono K: TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010;10:415-424.
3. Chung AS, Lee J, Ferrara N: Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505-514.
4. Ferrara N, Kerbel RS: Angiogenesis as a therapeutic target. Nature 2005;438:967-974. (Pubitemid 43093963)
5. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L: VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-371.
6. Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ: Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008;14:7068-7073.
7. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-745.
8. Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, Gururangan S, Friedman HS, Reardon DA: Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 2010;12:1300-1310.
9. Lucio-Eterovic AK, Piao Y, de Groot JF: Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009;15:4589-4599.
10. Norden AD, Drappatz J, Wen PY: Novel antiangiogenic therapies for malignant gliomas. Lancet Neurol 2008;7:1152-1160.
11. Greenfield JP, Jin DK, Young LM, Christos PJ, Abrey L, Rafii S, Gutin PH: Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurosurgery 2009;64:819-826, discussion 826-827.
12. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM: Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010;120:694-705.
13. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, De Maria R: Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010;468:824-828.
14. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C: Glioblastoma stemlike cells give rise to tumour endothelium. Nature 2010;468:829-833.
15. Fathers KE, Stone CM, Minhas K, Marriott JJ, Greenwood JD, Dumont DJ, Coomber BL: Heterogeneity of Tie2 expression in tumor microcirculation: influence of cancer type, implantation site, and response to therapy. Am J Pathol 2005;167:1753-1762. (Pubitemid 41713325)
16. Patten SG, Adamcic U, Lacombe K, Minhas K, Skowronski K, Coomber BL: VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment. BMC Cancer 2010;10:683.
17. Kuczynski EA, Viloria-Petit AM, Coomber BL: Colorectal cancer cell production of transforming growth factor beta decreases expression of endothelial cell vascular endothelial growth factor receptor 2. Cancer 2011, E-pub ahead of print.
18. Donovan D, Harmey JH, Toomey D, Osborne DH, Redmond HP, Bouchier-Hayes DJ: TGF beta-1 regulation of VEGF production by breast cancer cells. Ann Surg Oncol 1997;4:621-627. (Pubitemid 127725489)
19. Ferrari G, Pintucci G, Seghezzi G, Hyman K, Galloway AC, Mignatti P: VEGF, a prosurvival factor, acts in concert with TGF-beta1 to induce endothelial cell apoptosis. Proc Natl Acad Sci USA 2006;103:17260-17265. (Pubitemid 44788957)
20. Minami T, Murakami T, Horiuchi K, Miura M, Noguchi T, Miyazaki J, Hamakubo T, Aird WC, Kodama T: Interaction between hex and GATA transcription factors in vascular endothelial cells inhibits flk-1/KDR-mediated vascular endothelial growth factor signaling. J Biol Chem 2004;279:20626-20635. (Pubitemid 38656457)
21. Platten M, Wick W, Weller M: Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech 2001;52:401-410. (Pubitemid 32167828)
22. Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J: High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 2007;11:147-160. (Pubitemid 46209848)
23. Strege RJ, Godt C, Stark AM, Hugo HH, Mehdorn HM: Protein expression of Fas, Fas ligand, Bcl-2 and TGFbeta2 and correlation with survival in initial and recurrent human gliomas. J Neurooncol 2004;67:29-39. (Pubitemid 38418246)
24. Plate KH, Breier G, Weich HA, Mennel HD, Risau W: Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994;59:520-529. (Pubitemid 24357278)
25. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-848.
26. Chan AS, Leung SY, Wong M, Yuen ST, Cheung N, Fan YW, Chung LP: Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 1998;22:816-826. (Pubitemid 28328228)
27. Huang H, Held-Feindt J, Buhl R, Mehdorn HM, Mentlein R: Expression of VEGF and its receptors in different brain tumors. Neurol Res 2005;27:371-377. (Pubitemid 40734696)
28. Puputti M, Tynninen O, Sihto H, Blom T, Mäenpää HM, Isola J, Paetau A, Joensuu H, Nupponen NN: Amplification of KIT, PDG-FRA, VEGFR2 and EGFR in gliomas. Mol Cancer Res 2006;4:927-934. (Pubitemid 46121551)
29. Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN: Amplification of genes encoding KIT, PDGFR alpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol 2005;207:224-231. (Pubitemid 41404153)
30. Roberts WG, Palade GE: Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995;108:2369-2379.
31. Coomber BL, Stewart PA: Morphometric analysis of CNS microvascular endothelium. Microvasc Res 1985;30:99-115. (Pubitemid 16162308)
32. Coomber BL, Stewart PA, Hayakawa K, Farrell CL, Del Maestro RF: Quantitative morphology of human glioblastoma multiforme microvessels: structural basis of blood-brain barrier defect. J Neurooncol 1987;5:299-307. (Pubitemid 18030539)
33. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253-1259. (Pubitemid 46424067)
34. Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, Green RM, Pope WB, Liau LM, Mischel PS, Nelson SF, Elashoff R, Cloughesy TF: Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009;72:1217-1222.
35. Ali SA, McHayleh WM, Ahmad A, Sehgal R, Braffet M, Rahman M, Bejjani G, Friedland DM: Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg 2008;109:268-272.
36. Franceschi E, Brandes AA: Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe? Expert Rev Anticancer Ther 2011;11:657-660.
37. Goumans MJ, Liu Z, ten Dijke P: TGF-beta signaling in vascular biology and dysfunction. Cell Res 2009;19:116-127.
38. Minami T, Rosenberg RD, Aird WC: Transforming growth factor-beta 1-mediated inhibition of the flk-1/KDR gene is mediated by a 5′-untranslated region palindromic GATA site. J Biol Chem 2001;276:5395-5402.
39. Jenkins G: The role of proteases in transforming growth factor-beta activation. Int J Biochem Cell Biol 2008;40:1068-1078.
40. Kaminska B, Wesolowska A, Danilkiewicz M: TGF beta signalling and its role in tumour pathogenesis. Acta Biochim Pol 2005;52:329-337. (Pubitemid 41133768)